Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C4H5NO4.Zn.2H |
Molecular Weight | 329.598 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[Zn++].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O
InChI
InChIKey=POEVDIARYKIEGF-CEOVSRFSSA-L
InChI=1S/2C4H7NO4.Zn/c2*5-2(4(8)9)1-3(6)7;/h2*2H,1,5H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*2-;/m00./s1
Molecular Formula | H |
Molecular Weight | 1.0079 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H5NO4 |
Molecular Weight | 131.0868 |
Charge | -2 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Zn |
Molecular Weight | 65.409 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Zinc aspartate is an approved drug, used to treat zinc deficiency in humans. Zinc aspartate regulates the production of the growth hormone and sex hormones (it is necessary for the production of sperm cells and egg cells). It reduces the body’s susceptibility to infections and allergies. It promotes the proper secretion of insulin by the pancreas. Zinc deficiency causes: disorders in the functioning of the skin, the digestive system, the nervous system, the immunological system, and the skeletal system. Significant zinc deficiency can cause dwarfism and genital underdevelopment. Zinc aspartate suppresses experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS), as well as effector T cell functions in vitro.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0002286 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22350510 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Zincas Approved UseIndications for use:
complementation of zinc deficiency in the body |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Further studies on selective radioprotection by organic zinc salts and synergism of zinc aspartate with WR 2721. | 1990 Jun |
|
Oral zinc aspartate treats experimental autoimmune encephalomyelitis. | 2014 Dec |
|
Zinc and propolis reduces cytotoxicity and proliferation in skin fibroblast cell culture: total polyphenol content and antioxidant capacity of propolis. | 2014 Jul |
|
Congenital diseases of the gastrointestinal tract. | 2014 May |
Patents
Sample Use Guides
For inflammatory bowel disease, 300 milligrams of zinc aspartate (equal to 60 milligrams of elemental zinc) has been taken by mouth daily for four weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24913100
Zinc aspartate, at a concentration of 16 uM, increased human fibroblasts proliferation in cell culture
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:02:12 GMT 2023
by
admin
on
Fri Dec 15 16:02:12 GMT 2023
|
Record UNII |
4OC7QTI23H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
137 (Number of products:9660)
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12952MIG
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
4OC7QTI23H
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
236142
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
4OC7QTI23H
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
C87349
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
56841018
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
253-012-5
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
Zinc aspartate
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
36393-20-1
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
100000089091
Created by
admin on Fri Dec 15 16:02:12 GMT 2023 , Edited by admin on Fri Dec 15 16:02:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |